Daily Alpha · Reddit
· Midday Alpha · by Buzzberg Research
Highest engagement
by score · day changeGoldman review: hedge funds hold record Mag7 exposure while small-cap shorts hit an all-time high
The post summarizes a Goldman Sachs hedge fund review: record Magnificent Seven exposure, all-time-high Russell 2000 shorts, renewed industrial buying and cheap, oversold banks.
Goldman Sachs Review: Hedge Funds at Peak Exposure to Mag7 While Small Caps Short Soars to All-Time High The review
Crowded Mag7 longs sit alongside record small-cap shorts.
Source →Intel confirms 1.5 TB/s and 1.3 PFLOPS FP8 for its 480 GB LPDDR5X inference card
The author argues Intel's D-series sampling could benefit its data-center accelerator line while posing a capacity-bound inference share threat to NVIDIA.
Intel confirms 1.5 TB/s and 1.3 PFLOPS FP8 for its 480 GB LPDDR5X air-cooled inference card At the Open Compute
Watch ODM 480 GB card shipments.
Source →Treasury's average rate is 3.5% while the 10-year yields 5.2%
The author argues the rising average interest cost on rolling US Treasury debt pressures the fiscal outlook even if yields stop rising.
Treasury's averate rate is 3.5% while the 10yr yields 5.2% Going through Treasury's own numbers, the average interest rate on
Debt that rolls over gets more expensive at current yields.
Source →GameStop CEO Ryan Cohen has bought about $75M of stock since September 10
The post lays out Cohen's roughly $75M of insider buying in GameStop alongside declining game sales and growing collectibles revenue.
GameStop’s CEO has put about $75M into GameStop stock since Sep 10, and kept buying after it was already up
Insider buying continued while game sales decline.
Source →Bumble agrees to an all-cash sale to Ithaca Holdings at $6.05 per share
Bumble shareholders are to receive $6.05 per share in cash, a 138% premium to the unaffected share price.
Bumble Shareholders to Receive $6.05 Per Share in Cash Representing a 138% Premium to the Unaffected Share Price AUSTIN, Texas--(BUSINESSSource →
Most argued
by comments per upvoteA poster calls this the best time to accumulate NIFTY
The author argues NIFTY is the best place to accumulate now, citing fading Iran-war impact, slowing AI leadership, a strong domestic economy and SIP inflows, while avoiding small caps.
Best time to BUY! I think the bull run is starting, and this could be a great time to accumulateSource →
A poster argues Anthropic will not be profitable and plans to avoid its IPO
The author argues Anthropic's economics are unsustainable and plans to avoid its IPO.
Anthropic are not going to be profitable In 2025, Anthropic made $4b rev, -$46b costs for a net loss ofSource →
Biofrontera's Ameluz gets superficial BCC approval with Q2 near breakeven at a $14M valuation
Bullish DD argues Biofrontera's approved Ameluz PDT franchise, 80% gross margins and near-breakeven Q2 make its ~$14M market cap mispriced versus pre-revenue biotechs.
BFRI ($0.97): Ameluz sBCC approval + near-breakeven Q2 at a $14M valuation **Thesis:** Approved PDT product, growing revenue, 80% margins,Source →
SRL's run raises the question of what would trigger a trim before Syerston FID
The poster notes the Syerston feasibility study is done but the US$400m loan is conditional, the US/Nasdaq move needs approvals, and FID has not been reached.
SRL has had a ridiculous run. What would actually make you sell?
Watch Syerston final investment decision and loan finalisation.
Source →